Windlas Biotech Ltd Q3 FY2023 Concall Summary

Source transcript PDF: https://assets.stockscans.in/docs/ahruidz60si0pger4fudq5sb.pdf

Key Takeaways


CDMO: The Core Business in a Soft Patch

Hitesh Windlass: "We have to see it more on a YTD basis on an annual basis because from a quarterly perspective, our — while we are at whatever ₹400 crores, it is still too small. And the fluctuations can be there due to some new launches happened, some things got postponed, some multinationals not picking up inventory towards December and various small things."

Trade Generics: The Structural Growth Story

Hitesh Windlass: "But a huge number of people, almost 70% of India is living in villages and kasbahs, which are more than five and half lakh in number. And you cannot target this market of five and half lakh villages and kasbahs, by putting feet on the ground like a medical rep model. So this is where the whole trade generics space is."

Exports: Early Innings, Regulated-Market Push


Capacity Expansion: Injectables and Beyond


Margins, Capital Allocation & Leadership

Hitesh Windlass: "I do want to mention that for us, buybacks and dividends are both very, very important. And we see them as a way in which we can reward all shareholders."

Guidance & Commitments

CommitmentSpecificsTimeline
Injectable facility completionFacility build-out to finish; POs placed, amounts committedEnd of September 2023; most work by March 31, 2023
Sacubitril Valsartan launchGeneric launch in Indian marketQ4 FY23 (current quarter); shipment expected imminently
South Africa commercializationRecently approved product to begin suppliesQ4 FY23, or if not, Q1 FY24
Exports growth aspiration4x growth from ~₹20 crores to ~₹80 croresFour to five years
CDMO growthDouble-digit CAGR; "significant improvement" from current levelsThree to four years
Oral solids capacity expansionOne more expanded unit needed to meet aspirationBeyond 1–1.5 years (current capacity sufficient for that period)
Injectable facility asset returnsReach target asset return ratio1.5 to 2 years minimum from completion
Injectable market mix shiftTilt toward exports, away from CDMOToward end of four years from now
Working capital rangeMaintain within 70–85 daysOngoing, even as export and trade generics mix increases
CFO recruitmentNew CFO appointedThree to four months

Key Metrics

MetricQ3 FY23
Consolidated revenue₹119.7 cr, up 2% YoY
Consolidated EBITDA₹13.9 cr, up 7% YoY
Consolidated PAT₹9.2 cr, up 11% YoY
EBITDA margin11.7%, up from 11.1% YoY
Gross margin219 bps higher YoY
CDMO revenue₹85.9 cr, down 10% YoY; contributed 72% of consolidated revenue
Trade generics revenue₹24 cr, up 42% YoY; contributed 20% of consolidated revenue
Exports revenue₹8.4 cr, up 124% YoY; contributed 7% of consolidated revenue
Complex generics share~74% of revenue
Capacity utilization42.3%
Top 10 client concentrationLess than 40% of revenue
Top customer concentrationBelow 10% of revenue
Working capital~80–82 days, expected to remain within 70–85 days
Share buyback completed₹9.88 cr (3,87,238 shares) of ₹25 cr authorized, as of 25 Jan 2023